These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12379356)

  • 1. Polyclonal catalytic antibodies.
    Ostler EL; Resmini M; Brocklehurst K; Gallacher G
    J Immunol Methods; 2002 Nov; 269(1-2):111-24. PubMed ID: 12379356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytic antibody activity elicited by active immunisation. Evidence for natural variation involving preferential stabilization of the transition state.
    Gallacher G; Jackson CS; Searcey M; Goel R; Mellor GW; Smith CZ; Brocklehurst K
    Eur J Biochem; 1993 May; 214(1):197-207. PubMed ID: 8508792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An investigation of antibody acyl hydrolysis catalysis using a large set of related haptens.
    Odenbaugh AL; Helms ED; Iverson BL
    Bioorg Med Chem; 2000 Feb; 8(2):413-26. PubMed ID: 10722164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyclonal antibody catalytic variability.
    Stephens DB; Thomas RE; Stanton JF; Iverson BL
    Biochem J; 1998 May; 332 ( Pt 1)(Pt 1):127-34. PubMed ID: 9576860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A general kinetic approach to investigation of active-site availability in macromolecular catalysts.
    Resmini M; Gul S; Carter S; Sonkaria S; Topham CM; Gallacher G; Brocklehurst K
    Biochem J; 2000 Feb; 346 Pt 1(Pt 1):117-25. PubMed ID: 10657247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that the mechanism of antibody-catalysed hydrolysis of arylcarbamates can be determined by the structure of the immunogen used to elicit the catalytic antibody.
    Boucher G; Said B; Ostler EL; Resmini M; Brocklehurst K; Gallacher G
    Biochem J; 2007 Feb; 401(3):721-6. PubMed ID: 17020536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catalytic antibody therapy against the insecticide carbaryl.
    Wang J; Han Y; Liang S; Wilkinson MF
    Biochem Biophys Res Commun; 2002 Mar; 291(3):605-10. PubMed ID: 11855832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A polyclonal antibody preparation with Michaelian catalytic properties.
    Gallacher G; Jackson CS; Searcey M; Badman GT; Goel R; Topham CM; Mellor GW; Brocklehurst K
    Biochem J; 1991 Nov; 279 ( Pt 3)(Pt 3):871-81. PubMed ID: 1953683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyclonal antibodies and catalysis.
    Stephens DB; Wilmore BH; Iverson BL
    Bioorg Med Chem; 1994 Jul; 2(7):653-8. PubMed ID: 7858972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmenting the efficacy of anti-cocaine catalytic antibodies through chimeric hapten design and combinatorial vaccination.
    Wenthur CJ; Cai X; Ellis BA; Janda KD
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3666-3668. PubMed ID: 28709828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel reactions catalysed by antibodies.
    Golinelli-Pimpaneau B
    Curr Opin Struct Biol; 2000 Dec; 10(6):697-708. PubMed ID: 11114507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in hydrolytic antibody activity by change in haptenic structure from phosphate to phosphonate with retention of a common leaving-group determinant: evidence for the 'flexibility' hypothesis.
    Gul S; Sonkaria S; Pinitglang S; Florez-Alvarez J; Hussain S; Thomas EW; Ostler EL; Gallacher G; Resmini M; Brocklehurst K
    Biochem J; 2003 Dec; 376(Pt 3):813-21. PubMed ID: 12946271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for the selection of catalytic antibodies against organophosphorus nerve agents.
    Smirnov I; Belogurov A; Friboulet A; Masson P; Gabibov A; Renard PY
    Chem Biol Interact; 2013 Mar; 203(1):196-201. PubMed ID: 23123255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catalytic polyclonal antibodies.
    Stephens DB; Iverson BL
    Biochem Biophys Res Commun; 1993 May; 192(3):1439-44. PubMed ID: 8507208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional mimicry between anti-Tendamistat antibodies and alpha-amylase.
    Gonçalves O; Dintinger T; Blanchard D; Tellier C
    J Immunol Methods; 2002 Nov; 269(1-2):29-37. PubMed ID: 12379350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for 'lock and key' character in an anti-phosphonate hydrolytic antibody catalytic site augmented by non-reaction centre recognition: variation in substrate selectivity between an anti-phosphonate antibody, an anti-phosphate antibody and two hydrolytic enzymes.
    Sonkaria S; Boucher G; Flórez-Olvarez J; Said B; Hussain S; Ostler EL; Gul S; Thomas EW; Resmini M; Gallacher G; Brocklehurst K
    Biochem J; 2004 Jul; 381(Pt 1):125-30. PubMed ID: 15053743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigations into the development of catalytic activity in anti-acetylcholinesterase idiotypic and anti-idiotypic antibodies.
    Johnson G; Moore SW
    J Mol Recognit; 2009; 22(3):188-96. PubMed ID: 19051205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic antibodies with acetylcholinesterase activity.
    Johnson G; Moore SW
    J Immunol Methods; 2002 Nov; 269(1-2):13-28. PubMed ID: 12379349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyclonal antibody-catalysed hydrolysis of a beta-lactam.
    Ostler EL; Resmini M; Boucher G; Romanov N; Brocklehurst K; Gallacher G
    Chem Commun (Camb); 2002 Feb; (3):226-7. PubMed ID: 12120377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.